BRILIQUE® (ticagrelor)

BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†1

*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)1

†BRILIQUE (ticagrelor) 90mg twice daily  in combination with  acetylsalicylic acid (ASA) is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg twice daily is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment

 

Self serving IDA
Self serving IDA

  • Click the guide on the left to discover how Brilique can inform your prescribing decisions

Brilique Product Information

Prescribing BRILIQUE (ticagrelor) 60mg

BRILIQUE (ticagrelor) 60mg is indicated for use in a high-risk population

BRILIQUE (ticagrelor) 60mg twice daily in combination with ASA is recommended when an extended treatment is required for patients with a history of MI of at least 1 year and a high risk of an atherothrombotic event.1

If a patient meets 1 or more DRAMA criteria, they can be considered for extended treatment with BRILIQUE 60 mg.1,15 The DRAMA criteria is defined as:

Pegasus inclusion criteria
Pegasus inclusion criteria

a. Chronic non-end-stage renal dysfunction. Estimated Creatinine Clearance < 60 mL/min.
b. Multivessel coronary artery disease based on an interim snapshot of the data, after completion of enrollment but during ongoing trial and data cleaning

Continuation with BRILIQUE (ticagrelor) 60mg after 1 year’s DAPT treatment

BRILIQUE (ticagrelor) 60mg twice daily  in combination with ASA may be initiated without interruption as a continuation therapy after the initial one-year treatment with BRILIQUE (ticagrelor) 90mg twice daily  or other ADP receptor inhibitor therapy in eligible patients with prior MI and a high risk of another atherthrombotic event, unless contraindicated.1

BRILIQUE 60mg is taken twice a day, once in the morning and once in the evening, in combination with ASA once daily
BRILIQUE 60mg is taken twice a day, once in the morning and once in the evening, in combination with ASA once daily
  • BRILIQUE 60mg twice daily may also be initiated up to 2 years from MI, or within 1 year of stopping previous ADP receptor inhibitors1
  • There are limited data on the efficacy and safety of BRILIQUE 60mg twice daily beyond 3 years of extended treatment1

BRILIQUE (ticagrelor) 60mg can be initiated regardless of the prior P2Y12 inhibitor used

Treatment with BRILIQUE (ticagrelor) 60mg twice daily in combination with ASA may be started without interruption or as continuation therapy after the initial one-year treatment with BRILIQUE (ticagrelor) 90mg twice daily, or other ADP receptor inhibitor therapy, in high risk post-MI patients1

  • In the PEGASUS-TIMI 54 study, 84% of patients received clopidogrel plus aspirin as their previous antiplatelet therapy15
Back to top